Table 1.
Clinical data and MS history.
| Age (years) | Sex | Years since MS diagnosis | Start date Clad | Duration Nat therapy years (cycles) | Latency Nat-Clad (weeks) | MRI activity during Nat | Number of new T2 (Gd+) lesions (years prior Nat) | Number of relapses last years prior Nat | Annual relapse rate before Nat | DMTs before Nat | Azathioprine yes/ no | JCV antibody index | Comorbidity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clad1 | 55 | m | 16.5 | Jan 2019 | 5.2 (53) | 14 | No | 1 (0) | 2 | 1.0 | 2 | No | 1.13 | Degenerative LWS syndrome |
| Clad2 | 48 | f | 10 | Apr 2018 | 3.9 (41) | 16 | No | 1 (0) | 2 | 0.83 | 2 | No | 4.55 | Meningioma frontal left |
| Clad3 | 44 | m | 5.5 | Mar 2018 | 3 (30) | 23 | No | NA | 2 | 0.8 | 1 | No | 0.25 | Recurrent depression |
| Clad4 | 67 | f | 18 | Feb 2019 | 12.25 (93) | 17 | No | 0 (0) | 3 | 1.74 | 4 | Yes | 2.58 | Hysterectomy |
| Clad5 | 50 | f | 13 | Mar 2018 | 1.35 (19) | 17 | No | 0 (1) | 1 | 0.17 | 1 | No | 1.58 | |
| Clad6 | 50 | m | 20 | Mar 2018 | 9.38 (74) | 23 | Yes | 0 (0) | 1 | 0.28 | 3 | No | 0.58 | |
| Clad7 | 59 | f | 11 | May 2018 | 4.85 (53) | 17 | Yes | 2 (0) | 2 | 0.65 | 2 | Yes | 2.9 | RLS, recurrent depression, degenerative cervical spine alterations |
| Clad8 | 52 | f | 18 | Jan 2019 | 6.58 (65) | 13 | No | 0 (3) | 0 | 0.26 | 1 | No | 2.56 | |
| Clad9 | 57 | m | 28 | Oct 2018 | 6.75 (65) | 12 | No | NA | 3 | 0.47 | 2 | No | 2.7 | IDDM, hypercholesterolemia |
| Clad10 | 56 | m | 20 | Apr 2018 | 5.33 (54) | 9 | No | NA | 2 | 0.41 | 2 | No | 3.69 | |
| Clad11 | 37 | m | 12 | Apr 2018 | 0.96 (12) | 18 | Yes | 1 (0) | 1 | 0.36 | 4 | No | 1.68 | |
| Clad12 | 48 | f | 22 | Feb 2018 | 10.67 (97) | 9 | Yes | NA | 3 | 1.06 | 2 | Yes | 3.26 | Depression |
| Clad13 | 45 | f | 14 | Jun 2018 | 10 (41) | 12 | No | NA | 3 | 1.25 | 2 | No | 1.79 | Hypothyroidism |
| Clad14 | 47 | f | 11 | Apr 2018 | 1.08 (11) | 20 | No | 0 (1) | 1 | 0.71 | 1 | No | 2.9 | |
| Clad15 | 66 | f | 12 | Jan 2018 | 4.54 (48) | 14 | No | 0 (0) | 1 | 0.54 | 1 | No | 1.03 | |
| Clad16 | 57 | f | 8 | Oct 2018 | 2.83 (28) | 20 | No | 0 (0) | 1 | 1.16 | 1 | No | 2.21 | QuantiFERON test positive (no evidence for tuberculosis), spinal osteochondrosis, sulcus ulnaris syndrome |
| Clad17 | 65 | f | 21 | Mar 2019 | 6.75 (73) | 17 | No | NA | 2 | 0.63 | 2 | Yes | 1.74 | Trigeminal neuralgia, hypothyroidism |
Clinical data for all patients including disease duration, MS disease activity prior to cladribine treatment, JCV antibody index, comorbidities, and latency between natalizumab and cladribine. Clad, cladribine; DMTs, disease modifying therapies; Gd, gadolinium; IDDM, insulin dependent diabetes mellitus; JCV, John Cunningham virus; LWS, MRI, magnetic resonance imaging; MS, multiple sclerosis; NA, not available; Nat, natalizumab; RLS.